The Economic Times
English EditionEnglish Editionहिन्दीગુજરાતી
| 07 August, 2020, 09:02 AM IST | E-Paper

    Khomba Singh

    Articles by the author

    India eyes $40 billion global generic market; patents held by MNCs to expire in over 3 yearsNew drug pricing formula to cost Ranbaxy, GSK Dr Reddy's & others Rs 1,300 croreNGO set to challenge market-linked drug pricing formula in Supreme CourtAnaljit Singh raises stake in Max India; acquires 5.29 million shares
    Ranbaxy misses out on first-day launch of hypertension drug's generic versionMitsui & Co buys additional 25% stake in Arch Pharmalabs for Rs 372 croreDrug pricing policy may be finalised next weekGovernment gets two weeks to finalise drug pricing policy
    Law Ministry favours giving CCI power to vet pharma buys by MNCs and foreign investorsDelhi High Court dismisses Roche's patent suit against CiplaPricing of imported drugs under regulatory scannerNovo Nordisk to rope in health workers for diabetes care to poor
    Submit mandatory safety report of new drugs or face license cancellation: DCGI to Drug companiesUSFDA lifts sales ban as Indian drug companies take corrective actionsFIPB gives nod to eight pharma FDI proposalsFIPB to take up 10 pharma FDI proposals on Friday
    Fresenius Kabi to pay higher compensation to clinical trial victimsSupreme Court defers Novartis' patent appeal to September 11Intellectual Property Appellate Board postpones Bayer's 
compulsory licence appealLack of compensation norms for clinical trials results in exploitation of poor patients
    Ranbaxy Laboratories launches authorized generic Actos in USCRO market to double to $1 billion by 2016: Frost & SullivanLinking patented drug price to per capita income may hit generic drug makers: ExpertsWindfall likely for Ranbaxy Laboratories after FDA says no to Watson Pharmaceuticals
    Prices of patented medicines may come down by a third if panel's recommendation acceptedRanbaxy Laboratories shifts production of Lipitor generic to MohaliFirst-time MP, Jyoti Mirdha makes life difficult for pharmaceutical companies and drug regulatorsFree samples to doctors to be now considered as taxable income
    Ranbaxy Lab may have abandoned sleep disorder generic drug Provigil launchDelhi High Court gives Natco Pharma a week to respond to Bristol-Myers Squibb contempt chargesGeneric business may hit drug exports of Indian firms like Cipla and NatcoNatco Pharma, Bristol-Myers Squibb face off in Court over sale of dasatinib clone
    Companies like Eli Lilly, Biocon & Cadila oppose move to cut margin on insulinForeign Investment Promotion Board defers pharmaceuticals sector FDI proposalsGovernment may ease FDI norms in pharmaceutical industryLupin to challenge Pregabalin ruling by US court
    Eye care chain Centre for Sight in stake sale talksPharma companies fear generics will erode their marginsOmbudsman proposed to deal with doctor-drug firm nexusGovernment to meet pharma companies, MCI to end freebies to doctors
    FDI proposals of some pharma MNCs may get nodStrides Arcolabs' Agila Specialties Pharma Corporation forms JV with Jamp PharmaDogged with corruption, drug regulation is in poor health and ineffectiveQuadria Capital plans to raise $300 mn healthcare fund
    Five retailers led by Walgreen sue Pfizer, Ranbaxy for Lipitor generic delayRajasthan Venture Capital Fund buys minority stake in International Oncology for Rs 20 crFDI conditions only for acquisitions of over 49% stake or management control: Pharma DepartmentMinistries' fight over pharma FDI norms lands on Manmohan Singh's table
    Actis Capital LLP to exit Nilgiris Dairy FarmGovernment to ensure Indian pharma firms to make, sell drugs after being acquired by a foreign firmPharma department to meet drug firms to discuss making the drug marketing code mandatoryHealth ministry plans inspection fee to expand DCGI staff
    FIPB defers Massimo Dutti's India forayDrug marketing code may become mandatory soonNPPA likely to revise prices of 50 drugs soonHow to protect your baby from sun heat
    Hypertension on rise in urban India, studyWe will prove the poor can access healthcare: Dr Devi Prasad Shetty, Narayana HrudayalayaFree medicines to all patients in government hospitals from NovemberMore nations adopting Indian intellectual property regulations for drug manufacturing
    Daiichi Sankyo and Ranbaxy Launch hybrid business in VenezuelaMax India likely to split healthcare and financial businesses into separate entitiesDrug export up 27% at Rs 60,000 crore in FY 12Ranbaxy and Dr Reddy's to take a hit as Lipitor market shrinks 96%
    Tata Group weighs options to exit Advinus TherapeuticsSuper Religare Labs gets Rs 370 crore infusion from IFC and NYLIM Jacob Ballas IndiaCost-based pricing to hit exports, says Indian Pharmaceutical AllianceConsumers ready to adopt mobile technology in healthcare: PwC Global Healthcare
    Panel to look into Drug Controller General of India's working meetsInter-ministerial panel to finalise norms for MNC buys in drug companiesSal Pharma and Pan Drugs gets FDA warning letter for not registering drugsGovernment plans to reduce pharma industry's dependence on China
    FIPB starts clearing investments in drug sector againHelpingDoc launches free online appointments with doctors in NCRTeva Pharmaceuticals will not be launching Atorvastatin, generic version of LipitorRanbaxy to relaunch bessling brand
    Ranbaxy to relaunch bessling brand
    28 May 2012 10:51 PM IST
    Centre for Sight acquires majority stake in New Vision Laser CentrePharma companies unresponsive to overcharging noticesLupin recall contraceptive drug in USVolatile market takes toll on Pharmaceuticals and healthcare IPO plans
    Ranbaxy plans to re-launch skincare brand Sotret in USNGOs, MP Jyoti Mirdha demand wider drugs under price controlBayer demands withdrawal of Natco Pharma's compulsory licenceGroup of Ministers to take NGOs & MPs views ahead of finalising drug pricing policy
    New drug-pricing policy to determine prices at which firms can sell essential medicines in marketPharma companies open to milder alternative pricing mechanismFIPB may be allowed to clear foreign buys in pharma companiesGovernment plans a crackdown on pharma firms selling drugs as dietary supplements
    Drug pricing policy: IPA agrees to PMEAC's hybrid formulaGoM on drug pricing defers decision, next meet on FridayShantha Biotech hopes for revival as it aims to relaunch Shan5Philips launches ClearVue; to launch series of locally developed products
    Ranbaxy Laboratories's net profit zooms four-fold at Rs 1,246 crore
    The Economic Times